NCT02820311View on ClinicalTrials.gov

Thorough QT (TQT) Study of TD-4208 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Cardiac Repolarization in Healthy Subjects

Interventions

DRUG

TD-4208 175 mcg

via nebulizer

DRUG

TD-4208 700 mcg

via nebulizer

DRUG

Placebo for TD-4208

via nebulizer

DRUG

Moxifloxacin 400 mg

oral

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Lead Sponsor

Collaborators (1)

Theravance Biopharma

All Listed Sponsors

collaborator

Theravance Biopharma

INDUSTRY

lead

Mylan Inc.

INDUSTRY

NCT02820311 - Thorough QT (TQT) Study of TD-4208 in Healthy Subjects | Biotech Hunter | Biotech Hunter